BTIG Research Assumes Agilent Technologies Inc to Buy

Brokerage firm BTIG Research Assumes its rating on Agilent Technologies Inc(NYSE:A). The shares have been rated Buy. The rating by BTIG Research was issued on Jul 22, 2016.

In a different note, On May 26, 2016, Cowen & Company said it Maintains its rating on Agilent Technologies Inc. In the research note, the firm Raises the price-target to $47.00 per share. The shares have been rated ‘Outperform’ by the firm. On May 11, 2016, Goldman Sachs said it Maintains its rating on Agilent Technologies Inc. In the research note, the firm Raises the price-target to $47.00 per share. The shares have been rated ‘Buy’ by the firm.

Agilent Technologies Inc (A) made into the market gainers list on Thursdays trading session with the shares advancing 0.53% or 0.25 points. Due to strong positive momentum, the stock ended at $47.51, which is also near the day’s high of $47.75. The stock began the session at $47.19 and the volume stood at 19,45,322 shares. The 52-week high of the shares is $47.46 and the 52 week low is $33.115. The company has a current market capitalization of $15,466 M and it has 32,55,21,700 shares in outstanding.

Agilent Technologies Inc(A) last announced its earnings results on May 16, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.02B. Analysts had an estimated revenue of $983.08M. Earnings per share were $0.44. Analysts had estimated an EPS of $0.39.

Several Insider Transactions has been reported to the SEC. On May 31, 2016, James Cullen (director) sold 16,697 shares at $45.78 per share price.Also, On May 20, 2016, Michael R. Mcmullen (CEO and President) sold 124,411 shares at $44.46 per share price.On May 20, 2016, Patrick Kaltenbach (Sr Vice President) sold 5,266 shares at $44.07 per share price, according to the Form-4 filing with the securities and exchange commission.

Agilent Technologies Inc. is engaged in the life sciences diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments software services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business the diagnostics and genomics business and the Agilent CrossLab business. The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics. The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business the genomics business and the nucleic acid solutions business. The Company’s Agilent CrossLab business segment combines its analytical laboratory services and consumables business.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *